Keywords: r-pr, campto, oked, first-line, indication, rhone-poulenc, rorer

R-PR's Campto OKed for first-line indication

Article | 29 July 1999

Rhone-Poulenc Rorer has received European approval to market itsanticancer therapy Campto (irinotecan) in combination with 5-fluorouracil and folinic acid for ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Drugs

Carac

fluorouracil

Efudex

Go to drug listing